Transgenic rats provide new models of human disease
Transgenic rats, created using a novel application of zinc finger nuclease (ZFN) technology, could aid the development of animal models of human diseases.
Transgenic rats, created using a novel application of zinc finger nuclease (ZFN) technology, could aid the development of animal models of human diseases. The technology enables the mutation of specific genes, which can be passed down heritably, according to the results of the study "Knockout Rats via Embryo Microinjection of Zinc Finger Nucleases", published in Science.
"Until now, rat geneticists lacked a viable technique for "knocking out", or mutating, specific genes to understand their function," Howard Jacob, Director of the Human and molecular Genetics Center at the Medical College of Wisconsin (WI, USA), explained in a statement.
The world’s first targeted knockout rat (left) was created using CompoZr zinc finger nuclease technology to knock-out the green fluorescent protein (GFP) gene in the GFP rat (right).Image Courtesy of Sigma-Aldrich Coporation and the Medical College of Wisconsin.
The breakthrough was made by scientists at the Medical College of Wisconsin, Sangamo Biosciences (CA, USA), Sigma-Aldrich (MO, USA), Open Monoclonal Technology (CA, USA) and INSERM (France). It is believed that the rats will aid understanding of physiology, endocrinology, neurology, metabolism, parasitology, growth and development, and cancer.
"We have invested our time and resources to develop the CompoZr platform because we see enormous potential in a technology that can precisely manipulate the genome of living organisms," David Smoller, President of Sigma-Aldrich's Research Biotech business unit, which markets ZFN technology through its CompoZr line, said in the statement. "We are proud to be part of the public–private collaboration developing the proof-of-concept for this technique, which we believe will become the standard for the creation of genetically engineered research animals."
www.mcw.eduwww.sangamo.comwww.sigmaaldrich.com http://openmonoclonaltechnology.com/index.html www.inserm.fr
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
